Antigen-Specific Antibody Discovery

The ability of LIBRA-seq™ to screen B cells against large libraries of antigens provides a critical advantage for antibody discovery efforts in various potential settings, including: screening of individual B cell samples simultaneously against a wide variety of antigens of interest; antigen targets that exhibit high sequence diversity; antibodies that are broadly reactive against different (but related) viruses; cross-reactivity against multiple orthologs of the same antigen to facilitate preclinical evaluation of lead antibodies; and others.